Novo Nordisk A/S (NOVO_B) Wins EU Authorisation for Haemophilia A Treatment

Novo Nordisk presented baseline data for its Phase III ARTEMIS trial of ziltivekimab, an IL-6 inhibitor, at AHA 2026. The trial aims to assess the drug's ability to reduce cardiovascular events post-heart attack.

Novo Nordisk submitted etavopivat, a sickle cell disease treatment, for approval in the U.S. and Europe. The drug, acquired via Forma Therapeutics, showed a 27% reduction in pain episodes. Novo aims to position it as a standard treatment. Separately, Flagship Pioneering and the Gates Foundation will collaborate on health and agriculture solutions, committing $25 million over five years.

Novo Nordisk (NVO) submitted regulatory applications for etavopivat, a treatment for sickle cell disease, to the FDA and EMA. The submissions are based on Phase 3 HIBISCUS study results showing a 27% reduction in vaso-occlusive crises. Regulatory decisions are expected in 2027. The drug has received Fast Track, Rare Pediatric Disease, and Orphan Drug designations.

BMO Capital Markets raised Novo Nordisk's (NVO) price target to $44 from $40, citing strong Wegovy sales, but kept a Market Perform rating. NVO stock is up 1.03% at $41.30, facing resistance at $41.85 and $42.41. Technical indicators show mixed momentum and derivatives data indicates a long bias but weak confirmation.

The Liver Meeting 2026 highlighted advancements in hepatitis delta, PBC, and MASH treatments. Vir Biotechnology's elebsiran and Mirum Pharmaceuticals' brelovitug showed promising phase 3 results for hepatitis delta, with regulatory submissions expected in 2027. GSK's bepirovirsen received FDA approval for hepatitis B. Merck's efinopegdutide and Altimmune's pemvidutide showed potential in MASH treatment. Real-world data indicated cost concerns with MASH therapies.

The FDA warned about a potential eye condition, NAION, linked to GLP-1 drugs. It requires manufacturers like Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) to update packaging warnings. Lawsuits allege insufficient warnings, while evidence of a link remains mixed. Both companies prioritize patient safety and monitor the issue.